High C-reactive protein to albumin ratio and the short-term survival prognosis within 30 days in terminal cancer patients receiving palliative care in a hospital setting

A retrospective analysis

Sang-Yhun Ju, MD, PhD\textsuperscript{a,}\textsuperscript{*}, Soo-Jin Ma, MD, PhD\textsuperscript{b}

Abstract
Survival estimates are very important to patients with terminal cancer. The C-reactive protein (CRP)/albumin ratio is associated with cancer outcomes. However, few studies have investigated the dose-response association in terminal cancer patients. Therefore, we aimed to evaluate the association between the CRP/albumin ratio and mortality in terminal cancer patients using a longitudinal analysis. We retrospectively investigated the electronic medical records of 435 inpatients with terminal cancer admitted to the palliative care unit of Yeouido St. Mary’s Hospital between October 8, 2015, and January 17, 2018. In total, 382 patients with terminal cancer were enrolled in the study. The serum CRP/albumin ratio measured at admission had a linear dose-response relationship with the risk of death among the terminal cancer patients ($P$ for linearity = .011). The multivariate analyses showed that the CRP/albumin ratio was an independent prognostic factor (Model 1, CRP/albumin ratio $>48.53 \times 10^{-5}$: HR = 2.68, 95% CI = 1.82–3.93; Model 2, tertile 2: HR = 1.91, 95% CI = 1.31–2.82 and tertile 3: HR = 3.66, 95% CI = 2.24–5.97). The relationship between a high CRP/albumin ratio and poor survival was a flat L-shape for survival time with an inflection point at approximately 15 days, while the relationship was not significant in terminal cancer patients who survived beyond 30 days. This study demonstrated that high CRP/albumin ratios are significantly and independently associated with the short-term survival prognosis of terminal cancer patients within 30 days.

Abbreviations: CI = confidence interval, CRP = C-reactive protein, ECOG = Eastern Cooperative Oncology Group, EMRs = electronic medical records, GPS = Glasgow prognostic score, IRB = Institutional Review Board, LDH = lactate dehydrogenase, NLR = neutrophil/lymphocyte ratio, ROC = receiver operating characteristic, SBP = systolic blood pressure.

Keywords: albumin, cancer, cohort study, C-reactive protein, death, palliative care

1. Introduction
Survival estimates are very important to patients with terminal cancer.\textsuperscript{[1]}\textsuperscript{–}[3] Patients who are admitted to palliative care hospitals and their families wish to know how much longer they have to live, and this topic is important for reorienting their priorities, particularly as they approach the end of life.\textsuperscript{[1]–[3]} However, physicians may experience difficulty in identifying terminal cancer patients with a short survival period. Published reviews have shown that clinicians’ predictions of survival are inaccurate and unreliable in advanced cancer.\textsuperscript{[4,5]} A recent meta-analysis showed that clinicians’ accuracy in prognostic estimates varied from 23% to 78% in a palliative care setting.\textsuperscript{[6]}

There are various prognostic tools, such as the palliative prognostic score, palliative prognostic index, and palliative performance scale.\textsuperscript{[6]–}[10] Although these prognostic tools have been validated, their clinical utility is limited due to their complexity and subjectivity.\textsuperscript{[7,8]} In a systematic review of candidate biomarkers in body fluids for the prediction of the risk of death in cancer patients, 7 prognostic biomarkers, namely, the lymphocyte count, white blood cell count, and serum levels of albumin, sodium, C-reactive protein (CRP), urea and alkaline phosphatase, were supported by Grade A evidence.\textsuperscript{[8]}

Increased levels of serum CRP in all stages of tumor growth have been associated with a poor prognosis.\textsuperscript{[9,10]} Amano et al divided the serum CRP levels into four groups to predict patient outcomes and clearly demonstrated an inverse dose-response relationship between CRP and patient survival.\textsuperscript{[9]} Furthermore, low levels of albumin measured at admission are associated with increased short-term and long-term mortality.\textsuperscript{[11]} It is well known that as the inflammation process progresses, the essential protein components of the body gradually decrease, leading to increased
mortality in advanced cancer patients. A meta-analysis of studies involving 4582 tumor patients demonstrated that a high CRP/albumin ratio is associated with a worse survival in various cancers and that this association is consistently significant independent of the cutoff value, cutoff value selection, treatment method, country, sample size, stage and cancer type. Recently, a cross-sectional study explored the association between the CRP/albumin ratio and clinical outcomes in terminal cancer and non-cancer patients. This study suggested that the CRP/albumin ratio was beneficial in the prediction of short-term survival within two weeks. Whether this association applies to terminal cancer patients with a longer survival is unclear. Moreover, few studies have focused on the dose-response association of the CRP/albumin ratio and mortality in terminal cancer patients. Thus, we aimed to elucidate the association between mortality and the CRP/albumin levels in terminal cancer patients using a longitudinal analysis.

2. Methods

2.1. Study design and patient selection

We retrospectively exploited data from electronic medical records (EMRs), including CRP, albumin and other clinical variables. The EMR data were obtained from an observational, longitudinal database at Yeouido St. Mary’s Hospital; this database has been previously described in detail. This study was approved by the Institutional Review Board (IRB) of Yeouido St. Mary’s Hospital (approval number: SC18RESI008; approval date: July 24, 2018). As this study was a retrospective review of EMRs, the requirement for informed consent was waived by the IRB.

In total, 435 inpatients with terminal cancer admitted between October 8, 2015 and January 17, 2018 were screened and considered eligible for this study if they were aged older than 20 years, they and/or their families had been informed of their illness being terminal cancer that has progressed to the end stage, and no curative treatment could be provided by their physicians. All patients signed a DNR (do-not-resuscitate) order and accepted a referral to the palliative care ward. The exclusion criteria were as follows: death within a day of admission and a blood test not being conducted. Therefore, 382 inpatients (87.8%) with terminal cancer were enrolled in the study (Fig. 1).

2.2. Data collection

The patients’ clinical information, including age, sex, Eastern Cooperative Oncology Group (ECOG) status, survival status, survival days, primary cancer site, systolic blood pressure (SBP), existence of dyspnea, metastasis and serum levels of CRP, albumin, neutrophil and lymphocyte fractions (%), lactate dehydrogenase (LDH), hemoglobin, creatinine and sodium, was collected from EMRs. The CRP/albumin ratio and neutrophil/lymphocyte ratio (NLR) were calculated, and both ratios were derived based on the same blood sampling. We defined the survival time as the period from the day of evaluation to the day of death.

2.3. Statistical analyses

The continuous variables are expressed as medians with interquartile ranges, and the categorical variables are expressed as counts and percentages. The cutoff values of the CRP/albumin ratio and NLR were analyzed by a survival significance analysis using Cutoff Finder. A receiver operating characteristic (ROC) curve was generated by plotting the sensitivity value against the false-positive rate (1-specificity). We assessed the predictive value of life expectancy <30 days based on 2×2 tables. The patients were also stratified into tertiles (tertile 1, 0.077 to less than 12.7; tertile 2, 12.9 to less than 41.8; and tertile 3, 42.17 to less than 194.4) based on the CRP/albumin ratio distribution. A Kaplan-Meier analysis with a log-rank test was used to assess the differences in the median survival time among the groups. The individual effect of each variable on the association with mortality was first tested in a univariate Cox regression model. Then, all covariates with \( P < .1 \) were tested in a multivariate Cox proportional hazards model. Notably, CRP, albumin and the CRP/albumin ratio were

---

**Figure 1.** Flow chart of the participant selection process.
separately evaluated in a multivariate Cox proportional hazards model. A log-log plot was used to determine whether the Cox proportional hazards assumptions of each variable were confirmed. If a violation of the proportional hazards assumption was observed, a time-varying coefficient was created for the covariate. We performed a dose-response analysis using the restricted cubic splines approach to further explore whether the associations between the serum CRP/albumin levels and risk or death were linear or nonlinear (STATA mkspline command). P values < .05 were considered statistically significant. The statistical analyses were performed using STATA 15.0 (StataCorp, College Station, TX).

3. Results

Using Cutoff Finder in the survival significance analysis, we classified the patients as having a low CRP/albumin ratio (n = 270, 70.68%) or a high CRP/albumin ratio (n = 112, 29.32%) using the cutoff value of 48.53 × 10−4 (Supplementary Figure 1A, http://links.lww.com/MD/D868: distribution of the CRP/albumin ratios in all 382 patients; Supplementary Fig. 1B, http://links.lww.com/MD/D868: hazard ratios of overall survival independent of the cutoff point for CRP/albumin in patients with terminal cancer). Regarding the NLR, a cutoff of 4.104 was found to be optimal for overall survival using a ROC curve analysis, and this value also yielded the lowest log-rank P value (P < .05) in the survival analysis. The patients were divided into the following two groups based on this cutoff value (Table 1): NLR < 4.104 (n = 73, 19.11%) and NLR ≥ 4.104 (n = 309, 80.89%). Using a cutoff value of 48.53 × 10−4 for the CRP/albumin ratio, life expectancy was assuming to be < 30 days, yielding an area under the curve (AUC) of 0.641 (95% CI 0.602–0.680), a sensitivity of 36.5% (95% CI 30.9%–42.4%), a specificity of 91.8% (95% CI, 84.4%–96.4%), a positive predictive value (PPV) of 92.9% (95% CI, 86.4%–96.9%), and a negative predictive value of 33.0% (95% CI, 27.4%–38.9%), a positive likelihood ratio of 4.42 (95% CI, 2.24–8.74), and a negative likelihood ratio of 0.692 (95% CI, 0.622–0.770).

Table 1

| Variables | Cases | Proportion | Median survival \( \pm \) CI | \( P \) |
|-----------|-------|------------|-----------------------------|-------|
| Age; median, IQR (year) | 70, 19 | 50.00 | 20 (15–25) | .275 |
| < 70 | 191 | 50.00 | 22 (18–26) | \( P < .001 \) |
| ≥ 70 | 191 | 50.00 | 22 (18–26) | \( P < .001 \) |
| Sex | | | | |
| Female | 187 | 48.95 | 22 (17–26) | .332 |
| Male | 195 | 51.05 | 21 (16–25) | \( P < .001 \) |
| Primary cancer, n % | | | | |
| Gastrointestinal cancer | 219 | 57.33 | 19 (16–24) | .991 |
| Thoracic neoplasm | 81 | 21.20 | 24 (13–29) | \( P < .001 \) |
| Urogenital neoplasm | 55 | 14.40 | 21 (15–26) | \( P < .001 \) |
| Head and neck neoplasm | 10 | 2.62 | 24 (14–31) | \( P < .001 \) |
| Hematologic malignancy | 9 | 2.36 | 24 (7–37) | \( P < .001 \) |
| Other cancer | 8 | 2.09 | 20 (5–10) | \( P < .001 \) |
| ECOG | | | | |
| ≤ 3 | 122 | 31.94 | 26 (23–31) | .011 |
| ≥ 3 | 260 | 68.06 | 19 (16–21) | \( P < .001 \) |
| Dyspnea | | | | |
| No | 250 | 65.45 | 24 (21–29) | .001 |
| Yes | 132 | 34.55 | 16 (11–18) | \( P < .001 \) |
| Metastasis | | | | |
| No | 54 | 14.14 | 28 (21–34) | .054 |
| Yes | 326 | 85.86 | 20 (16–23) | \( P < .001 \) |
| SBP, median, IQR (mmHg) | 120, 27 | 54.97 | 23 (17–26) | .533 |
| < 120 | 210 | 54.97 | 23 (17–26) | \( P < .001 \) |
| ≥ 120 | 172 | 45.03 | 21 (16–24) | \( P < .001 \) |
| CRP, median, IQR (mg/L) | 66.9, 107.9 | 60.99 | 29 (24–33) | .001 |
| < 94.05 | 233 | 60.99 | 29 (24–33) | \( P < .001 \) |
| ≥ 94.05 | 149 | 39.01 | 13 (11–16) | \( P < .001 \) |
| Albumin, median, IQR (g/dL) | 2.83, 0.82 | 43.98 | 14 (12–16) | .001 |
| < 2.715 | 168 | 43.98 | 14 (12–16) | \( P < .001 \) |
| ≥ 2.715 | 214 | 56.02 | 28 (25–32) | \( P < .001 \) |
| CRP/albumin ratio | | | | |
| Median, IQR (×10⁻⁴) | 25, 45.3 | 70.68 | 27 (24–31) | .001 |
| < 48.53 | 270 | 70.68 | 27 (24–31) | \( P < .001 \) |
| ≥ 48.53 | 112 | 29.32 | 12 (9–15) | \( P < .001 \) |
| NLR, median, IQR | 5.58, 9.37 | 19.11 | 33 (28–38) | .001 |
| < 4.104 | 73 | 19.11 | 33 (28–38) | \( P < .001 \) |
| ≥ 4.104 | 309 | 80.89 | 18 (15–21) | \( P < .001 \) |
| LDH, median, IQR (IU/L) | 644.5, 623 | 50.00 | 26 (21–30) | .001 |
| < 644.5 | 191 | 50.00 | 26 (21–30) | \( P < .001 \) |
| ≥ 644.5 | 191 | 50.00 | 18 (14–22) | \( P < .001 \) |
| Creatinine, median, IQR (mg/dL) | 0.71, 0.63 | 50.52 | 21 (17–24) | .614 |
| < 0.71 | 193 | 50.52 | 21 (17–24) | \( P < .001 \) |
| ≥ 0.71 | 189 | 49.48 | 21 (16–26) | \( P < .001 \) |
| Sodium, median, IQR (mmol/L) | 132.7 | 50.79 | 18 (14–22) | .299 |
| < 132 | 194 | 50.79 | 18 (14–22) | \( P < .001 \) |
| ≥ 132 | 188 | 49.21 | 24 (20–27) | \( P < .001 \) |
| Hemoglobin, median, IQR (g/dL) | 10.4, 2.7 | 51.31 | 21 (17–24) | .647 |
| < 10.4 | 196 | 51.31 | 21 (17–24) | \( P < .001 \) |
| ≥ 10.4 | 186 | 48.69 | 22 (16–26) | \( P < .001 \) |

CI = confidence interval, ECOG = Eastern Cooperative Oncology Group, HR = hazard ratio, IQR = interquartile ratio, NLR = neutrophil to lymphocyte ratio, SBP = systolic blood pressure.

Optimal cutoff value with a minimum P value using a log-rank test (http://molpath.charite.de/cutoff/).

If a violation of the proportional hazards assumption was observed, a time-varying coefficient was created for the covariate. We performed a dose-response analysis using the restricted cubic splines approach to further explore whether the associations between the serum CRP/albumin levels and risk or death were linear or nonlinear (STATA mkspline command). P values < .05 were considered statistically significant. The statistical analyses were performed using STATA 15.0 (StataCorp, College Station, TX).
Univariate Cox regression analysis of mortality in patients with terminal cancer.

| Variables                        | HR    | 95% CI       | P     |
|----------------------------------|-------|--------------|-------|
| Age, year                        |       |              |       |
| <70                              | 1     |              |       |
| ≥70                              | 0.88  | 0.70–1.11    | .285  |
| Sex                              |       |              |       |
| Female                           | 1     |              |       |
| Male                             | 1.12  | 0.89–1.41    | .342  |
| Primary cancer site              |       |              |       |
| Gastrointestinal cancer          | 1     |              |       |
| Thoracic neoplasm                | 1.01  | 0.77–1.34    | .924  |
| Urogenital neoplasm              | 1.00  | 0.70–1.43    | .989  |
| Head and neck neoplasm           | 0.84  | 0.40–1.80    | .645  |
| Hematologic malignancy           | 1.17  | 0.63–2.32    | .646  |
| Other cancer                     | 0.92  | 0.42–1.95    | .818  |
| ECOG                             |       |              |       |
| <3                               | 1     |              |       |
| ≥3                               | 1.40  | 1.07–1.83    | .013  |
| Dyspnea                          |       |              |       |
| No                               | 1     |              |       |
| Yes                              | 1.58  | 1.25–2.00    | <.001 |
| Metastasis                       |       |              |       |
| No                               | 1     |              |       |
| Yes                              | 1.37  | 0.99–1.90    | .06   |
| Serum sodium (mmol/L)            |       |              |       |
| <120                             | 1     |              |       |
| ≥120                             | 1.07  | 0.85–1.35    | .542  |
| CRP (mg/L)                       |       |              |       |
| <0.05                            | 1     |              |       |
| ≥0.05                            | 3.01  | 2.07–4.38    | <.001 |
| Albumin (g/dL)                   |       |              |       |
| ≥2.715                           | 1     |              |       |
| <2.715                           | 1.97  | 1.56–2.48    | <.001 |
| CRP/Albumin ratio (×10⁻⁴)        |       |              |       |
| <48.53                           | 1     |              |       |
| ≥48.53                           | 3.17  | 2.17–4.63    | <.001 |
| Tertile 1                        | 1     |              |       |
| Tertile 2                        | 2.20  | 1.51–3.21    | <.001 |
| Tertile 3                        | 4.63  | 2.88–7.44    | <.001 |
| NLR                              |       |              |       |
| <4.104                           | 1     |              |       |
| ≥4.104                           | 1.97  | 1.43–2.71    | <.001 |
| LDH (IU/L)                       |       |              |       |
| <644.5                           | 1     |              |       |
| ≥644.5                           | 1.46  | 1.16–1.84    | .001  |
| Creatinine (mg/dL)               |       |              |       |
| <0.71                            | 1     |              |       |
| ≥0.71                            | 0.96  | 0.76–1.21    | .716  |
| Serum sodium (mmol/L)            |       |              |       |
| ≥132                             | 1     |              |       |
| <132                             | 1.76  | 1.21–2.56    | .003  |
| Hemoglobin (g/dL)                |       |              |       |
| <10.4                            | 1     |              |       |
| ≥10.4                            | 0.95  | 0.75–1.20    | .654  |

The variables that were significant (P < .1) in the univariate analysis were included in the multivariate Cox regression analysis of mortality (Table 3). The multivariate analysis revealed that the CRP/albumin ratio was an independent predictor of mortality.

Table 3

Multivariate Cox regression analysis of mortality in patients with terminal cancer.

| Variables                        | Model 1 |         | P value | Model 2 |         | P value |
|----------------------------------|---------|---------|---------|---------|---------|---------|
| Variables                        | HR      | 95% CI  |         | HR      | 95% CI  |         |
| Age, year                        |         |         |         |         |         |         |
| <70                              |         |         |         |         |         |         |
| ≥70                              |         |         |         |         |         |         |
| Sex                              |         |         |         |         |         |         |
| Female                           |         |         |         |         |         |         |
| Male                             |         |         |         |         |         |         |
| Primary cancer site              |         |         |         |         |         |         |
| Gastrointestinal cancer          |         |         |         |         |         |         |
| Thoracic neoplasm                |         |         |         |         |         |         |
| Urogenital neoplasm              |         |         |         |         |         |         |
| Head and neck neoplasm           |         |         |         |         |         |         |
| Hematologic malignancy           |         |         |         |         |         |         |
| Other cancer                     |         |         |         |         |         |         |
| ECOG                             |         |         |         |         |         |         |
| <3                               |         |         |         |         |         |         |
| ≥3                               |         |         |         |         |         |         |
| Dyspnea                          |         |         |         |         |         |         |
| No                               |         |         |         |         |         |         |
| Yes                              |         |         |         |         |         |         |
| Metastasis                       |         |         |         |         |         |         |
| No                               |         |         |         |         |         |         |
| Yes                              |         |         |         |         |         |         |
| Serum sodium (mmol/L)            |         |         |         |         |         |         |
| ≥120                             |         |         |         |         |         |         |
| <120                             |         |         |         |         |         |         |
| CRP (mg/L)                       |         |         |         |         |         |         |
| <0.05                            |         |         |         |         |         |         |
| ≥0.05                            |         |         |         |         |         |         |
| Albumin (g/dL)                   |         |         |         |         |         |         |
| ≥2.715                           |         |         |         |         |         |         |
| <2.715                           |         |         |         |         |         |         |
| CRP/Albumin ratio (×10⁻⁴)        |         |         |         |         |         |         |
| <48.53                           |         |         |         |         |         |         |
| ≥48.53                           |         |         |         |         |         |         |
| Tertile 1                        |         |         |         |         |         |         |
| Tertile 2                        |         |         |         |         |         |         |
| Tertile 3                        |         |         |         |         |         |         |
| NLR                              |         |         |         |         |         |         |
| <4.104                           |         |         |         |         |         |         |
| ≥4.104                           |         |         |         |         |         |         |
| LDH (IU/L)                       |         |         |         |         |         |         |
| ≤644.5                           |         |         |         |         |         |         |
| >644.5                           |         |         |         |         |         |         |

The patients with a high CRP/albumin ratio (≥48.53 × 10⁻⁴) had a 2.7-fold higher risk of death than those with a low CRP/albumin ratio (<48.53 × 10⁻⁴) in Model 1 (HR = 2.68, 95% CI = 1.82–3.93; Fig. 2 A). The NLR (P = .004) and dyspnea (P = .031) were also independently associated with mortality. Using the first tertile of the CRP/albumin ratio as a reference in Model 2, the HR of the patients in the second and third tertiles of the CRP/albumin ratio were 1.91 (95% CI, 1.31–2.82) and 3.66 (95% CI, 2.24–5.97), respectively, indicating that a higher CRP/albumin ratio is independently associated with an increased risk of death (Fig. 2 B). The NLR (P = .016) and LDH (P = .048) were also independently associated with mortality. Moreover, other factors, such as ECOG, metastasis and serum sodium, were not related to the risk of mortality in this analysis. In addition, the multivariate analysis showed that CRP and albumin were significantly associated with mortality (Model 3, Supplementary Table 1, http://links.lww.com/MD/D868). The HRs of high CRP (>49.45 mg/L) and low albumin (<2.715 g/dL) were 2.15 (95% CI, 1.44–3.20) and 1.53 (95% CI, 1.18–1.97), respectively. The cubic spline curves showed a gradual increase in the risk of death as the CRP/albumin ratio increased, but there was no statistically significant nonlinearity between the CRP/albumin ratio and the risk of death (P for nonlinearity = .092). However, there was a significant linear relationship between the risk of death and the CRP/albumin ratio (P for linearity = .011). In the linear fitted model, compared with the lowest CRP/albumin ratio (0.05 × 10⁻⁴), the estimated HRs were 1.14 (95% CI, 1.10–1.18) for 10 × 10⁻⁴, 1.49 (95% CI, 1.35–1.65) for 30 × 10⁻⁴, 2.22
(95% CI, 1.81–2.72) for 60/C210/C04, 3.77 (95% CI, 2.69–5.30) for 100/C210/C04, and 7.34 (95% CI, 4.42–12.20) for 150/C210/C04 (Fig. 3).

In a time-dependent Cox model, after adjustment for ECOG, dyspnea, metastasis, serum sodium, LDH, and the neutrophil/lymphocyte ratio. The HR of a high CRP/albumin ratio was significantly higher than that of a low CRP/albumin ratio (HR=2.68, P<.001). The cumulative mortality hazard was significantly high in the highest tertile (P<.001). The HR of the highest tertile was significantly higher than that of the lowest tertile (HR=2.24, P<.001). T1, 0.077/C210/C04 to less than 12.7/C210/C04; T2, 12.7/C210/C04 to less than 41.8/C210/C04; and T3, 42.17/C210/C04 to less than 194.4/C210/C04. CRP/albumin ratio is treated as a time-varying covariate in this analysis. ECOG = Eastern Cooperative Oncology Group, T1 = tertile 1, T2 = tertile 2, T3 = tertile 3. P<.001 by Wald test.

4. Discussion

The serum CRP/albumin ratio at admission to palliative care was a simple biomarker for predicting the risk of mortality in terminal
cancer patients within 119 days of follow-up. The serum levels of the CRP/albumin ratio measured at admission were associated with the risk of death in terminal cancer patients. The serum CRP/albumin ratio measured at admission showed a linear dose-response relationship with the risk of death in terminal cancer patients. Notably, the results remained essentially unchanged after controlling for potential confounding factors, such as the NLR, ECOG, dyspnea, metastasis, serum sodium and LDH. Therefore, these data suggest that the CRP/albumin ratio could be an independent biomarker for predicting death in terminal cancer patients admitted to a hospital for palliative care. However, the overall median survival of the terminal cancer patients was 21 days. The relationship between a high CRP/albumin ratio and poor survival was a flat L-shape for survival time with an inflection point at approximately 15 days, while it was not significant in terminal cancer patients surviving beyond 30 days. These findings are consistent with a previously reported finding linking the CRP/albumin ratio to short-term survival within two weeks in cancer and noncancer patients.[14] In addition, we observed that the CRP/albumin ratio was a useful independent predictor of the short-term survival prognosis within 30 days in terminal cancer patients.

Several mechanisms might help explain the association between high levels of CRP to albumin ratio and the shortened survival in terminal cancer patients.[12] Proinflammatory cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), can induce CRP production in the liver and contribute to systemic inflammation, which can lead to the gradual loss of important protein components in the body and subsequent death in cancer patients.[13] A chronic systemic inflammatory response results in the clinical features of cancer cachexia, that is, the progressive loss of weight.[18] The serum albumin concentration is negatively correlated with weight loss, while the serum CRP concentration is known to be positively correlated with weight loss.[12] Hypoalbuminemia has been suggested to predict the progressive decline of patients with advanced cancer.[12,18] The serum albumin levels at later stages of tumorigenesis could be significantly decreased by TNF-induced increases in the permeability of the microvasculature and the suppression of albumin synthesis induced by IL-1 and IL-6, whereas no or slight hypoalbuminemia occurs at the beginning of the disease.[12,13] Serum CRP levels have been associated with progressive stages of cancer and terminal cancer patients.[10,17] The higher the tumor stage, the greater the inflammatory response, and the higher the serum CRP levels.[9] These results support the notion that terminal cancer is related to a systemic inflammatory response and malnutrition, resulting in the death of the patient. Additionally, terminal cancer patients lack sufficient metabolic capability to respond to anti-inflammatory drugs and nutritional supplementation due to the spread of the disease state and multi-organ dysfunction.

Several previous meta-analyses investigating the cutoff values of the CRP/albumin ratio in relation to the prognosis of patients reported that the cutoff values differed among studies, thus reflecting differences in the characteristics of the patients across studies.[13,19,20] In this study, we evaluated the CRP/albumin ratio as a prognosis index of survival in terminal cancer inpatients. The 30-day mortality prediction by a CRP/albumin ratio cutoff value of 48.53 × 10^-4 is considered to have moderate accuracy with an AUC of 0.641 according to a ROC analysis and a PPV of 92.9%. Further investigation is needed to clarify the optimal cutoff values of the serum CRP/albumin ratio for predicting death in terminal cancer patients in various settings, such as hospitalization, home and consultation-based palliative care. The present analysis was not conducted separately using training and test datasets. Given that a general cutoff value for the CRP/albumin ratio has not been previously determined, we concluded that it could be better to present data cutoff values in many patients. Thus, this study focuses on presenting hospital data cutoff values as a training data set.

The Glasgow prognostic score (GPS) and modified GPS, which merges the elevated level of CRP (≥1.0mg/dL) and the lowered level of albumin (<3.5g/dL), are prognostic scores for cancer patients.[21–23] However, most patients in the present study had high levels of CRP and low levels of albumin (CRP ≥ 1 mg/dL, n = 373, 97.64%; albumin < 3.5 g/dL, n = 329, 86.13%; Supplementary Table 2, http://links.lww.com/MD/D868). Thus, the two prognostic scores might be inappropriate because terminal cancer inpatients who are no longer receiving curative treatment are in a severe condition approaching death. In contrast, the CRP/albumin ratio is based on the levels of CRP and albumin, resulting in a continuous value; thus, this ratio can reflect the inflammatory and nutritional status of patients at all stages of cancer. The plausible mechanism of the independent value of the CRP/albumin ratio in terminal cancer is likely to be complex. CRP and albumin can be considered valid markers of systemic inflammation and components of the criteria for cancer cachexia.[18] In a systematic review, serum CRP and albumin were reported to have prognostic values of the systemic inflammatory response in patients with advanced cancer.[17] It may be possible to combine CRP and albumin into a single index to predict death in terminal cancer patients. Furthermore, the CRP/albumin ratio can be calibrated based on how well the predicted probability of survival based on this prognostic model matches real data.[24] This study was applied only in terminal cancer patients at a single palliative care facility and is not applicable to all terminally ill patients. We excluded 10 (2.3%) patients who died within a day of admission to avoid the impact of left censored data and 43 (10.1%) patients who had missing CRP and albumin data, which could have affected our outcome regarding the CRP/albumin ratio. Nevertheless, the present study provides insight as this study is the first to analyze the dose-response relationship between the CRP/albumin ratio and mortality in terminal cancer inpatients. In conclusion, this study demonstrated that high levels of the CRP/albumin ratio are significantly and independently associated with the risk of mortality in terminal cancer patients hospitalized for palliative care.

Acknowledgments

The authors would like to thank Eunhyung Cho and Hyunhwa Seo from the Medical Record Team of St. Mary’s Hospital for assistance with the data collection. We also thank Youngdong Seo and Kyoungsook Park from St. Mary’s Hospital Library for assistance with this project.

Author contributions

Conceptualization: Sang-Yyun Ju, Soo-Jin Ma.
Data curation: Sang-Yyun Ju, Soo-Jin Ma.
Investigation: Sang-Yyun Ju, Soo-Jin Ma.
Methodology: Sang-Yyun Ju, Soo-Jin Ma.
Writing – original draft: Sang-Yyun Ju, Soo-Jin Ma.
Sang-Yyun Ju orcid: 0000-0002-0553-7128.
References

[1] Greisinger AJ, Lorimor RJ, Aday LA, et al. Terminally ill cancer patients. Their most important concerns. Cancer Pract 1997;5:147-54.

[2] Innes S, Payne S. Advanced cancer patients’ prognostic information preferences: a review. Palliat Med 2009;23:29–39.

[3] Parker SM, Clayton JM, Hancock K, et al. A systematic review of prognostic/end-of-life communication with adults in the advanced stages of a life-limiting illness: patient/caregiver preferences for the content, style, and timing of information. J Pain Symptom Manag 2007;34:81–93.

[4] Chow E, Harth T, Hruby G, et al. How accurate are physicians’ clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol (Royal College of Radiologists (Great Britain)) 2001;13:209–18.

[5] Parker SM, Clayton JM, Hancock K, et al. A systematic review of prognostic/end-of-life communication with adults in the advanced stages of a life-limiting illness: patient/caregiver preferences for the content, style, and timing of information. J Pain Symptom Manag 2007;34:81–93.

[6] White N, Reid F, Harris A, et al. A Systematic Review of Predictions of Survival in Palliative Care: How Accurate Are Clinicians and Who Are the Experts? PLoS One 2016;11:e0161407.

[7] Simmons CPL, McMillan DC, McWilliams K, et al. Prognostic Tools in Patients With Advanced Cancer: A Systematic Review. J Pain Symptom Manage 2015;50:963–70.e910.

[8] Reid VL, McDonald R, Nwosu AC, et al. A systematically structured review of biomarkers of dying in cancer patients in the last months of life: an exploration of the biology of dying. PLoS One 2017;12:e0175123.

[9] Amano K, Maeda I, Morita T, et al. Clinical implications of C-reactive protein as a prognostic marker in advanced cancer patients in palliative care settings. J Pain Symptom Manage 2016;51:860–7.

[10] Suh SY, Ahn HV. A prospective study on C-reactive protein as a prognostic factor for survival time of terminally ill cancer patients. Support Care Cancer 2007;15:613–20.

[11] Akhtar A, Mazri-Iraqi H, Atamna A, et al. Low Albumin Levels Are Associated with Mortality Risk in Hospitalized Patients. Am J Med. 2017;130:1465.e11-e19.

[12] McMillan DC, Watson WS, O’Gorman P, et al. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001;39:210–3.

[13] Li N, Tian GW, Wang Y, et al. Prognostic Role of the Pretreatment C-Reactive Protein/Albumin Ratio in Solid Cancers: A Meta-Analysis. Sci Rep 2017;7:4129.

[14] Miyamoto T, Fujitani M, Fukuyama H, et al. The C-Reactive Protein/Albumin Ratio Is Useful for Predicting Short-Term Survival in Cancer and Noncancer Patients. J Palliat Med 2019;22:532–7.

[15] Choi I, Choi R, Lee J, et al. Implementation of single source based hospital information system for the catholic medical center affiliated hospitals. Healthc Inform Res 2010;16:133–9.

[16] Budziesz J, Klaaschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One 2012;7:e51862.

[17] Dolan RD, McSorley ST, Horgan PG, et al. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta-analysis. Crit Rev Oncol Hematol 2017;116:134–46.

[18] Souza Cunha M, Wiegert EVM, Calixto-Lima L, et al. Relationship of nutritional status and inflammation with survival in patients with advanced cancer in palliative care. Nutrition (Burbank, Los Angeles County, Calif) 2018;51–52:98–103.

[19] Gao N, Yang RN, Meng Z, et al. The prognostic value of C-reactive protein/albumin ratio in nasopharyngeal carcinoma: a meta-analysis. Biosci Rep 2018;18:BSR20180686.

[20] Xu HJ, Ma Y, Deng F, et al. The prognostic value of C-reactive protein/albumin ratio in human malignancies: an updated meta-analysis. Onco Targets Ther 2017;10:3059–70.

[21] Jin J, Hu K, Zhou Y, et al. Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis. PLoS One 2017;12:e0184412.

[22] Shim SR, Kim SJ, Kim SI, et al. Prognostic value of the Glasgow Prognostic Score in renal cell carcinoma: a meta-analysis. World J Urol 2017;35:771–80.

[23] Yamada S, Fuji T, Yabusaki N, et al. Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter. Medicine (Baltimore) 2016;95:e3582.

[24] Hui D. Prognostication of survival in patients with advanced cancer: predicting the unpredictable? Cancer Control 2015;22:489–97.